Objectives: Several cross-sectional studies suggest that psychosocial factors are associated with non-adherence to chronic preventive maintenance medication (CPMM); however, results from longitudinal associations have not yet been systematically summarized. Therefore, the objective of this study was to systematically synthesize evidence of longitudinal associations between psychosocial predictors and CPMM non-adherence. Materials and methods: PUBMED, EMBASE, CINAHL, and PsychINFO databases were searched for studies meeting our inclusion criteria. The reference lists and the ISI Web of Knowledge of the included studies were checked. Studies were included if they had an English abstract, involved adult populations using CPMM living in Western countries, and if they investigated associations between psychosocial predictors and medication non-adherence using longitudinal designs. Data were extracted according to a literature-based extraction form. Study quality was independently judged by two researchers using a framework comprising six bias domains. Studies were considered to be of high quality if $four domains were free of bias. Psychosocial predictors for non-adherence were categorized into five pre-defined categories: beliefs/cognitions; coping styles; social influences and social support; personality traits; and psychosocial well-being. A qualitative best evidence synthesis was performed to synthesize evidence of longitudinal associations between psychosocial predictors and CPMM non-adherence. Results: Of 4,732 initially-identified studies, 30 (low-quality) studies were included in the systematic review. The qualitative best evidence synthesis demonstrated limited evidence for absence of a longitudinal association between CPMM non-adherence and the psychosocial categories. The strength of evidence for the review's findings is limited by the low quality of included studies.
Introduction
In conditions such as rheumatoid arthritis, diabetes, and hypertension, long-term therapy with chronic preventive maintenance medication (CPMM) is essential for reducing risks of disease progression, comorbidity, and mortality. However, sufficient medication adherence to CPMM is a prerequisite for reducing these risks. 1 Medication non-adherence, or the extent to which patients do not take their medications as agreed with their health care provider, averages 50% among patients suffering from chronic diseases in developed countries. 2 Non-adherence can result in poorer 
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Zwikker et al health outcomes and a lower quality of life in patients. 3 For example, patients who did not adhere to beta-blocker therapy were four and a half times more likely to have complications from coronary heart disease than those who adhered to therapy. 4 Non-adherence also affects health care utilization. For instance, poorer adherence among elderly patients with moderate-to-severe asthma was associated with a 5% increase in annual physician visits, whereas better adherence was associated with a 20% decrease in annual hospitalization. 5 Considering the undesired consequences of non-adherence to CPMM, interventions are needed to improve medication non-adherence. According to the World Health Organization (WHO), possible targets for these interventions can be divided into five domains:
2 socio-economic factors, health care system factors, condition-related factors, therapy-related factors, and patient-related factors. Although none of the factors within these domains are consistently associated with nonadherence across conditions, some tend to be better predictors of non-adherence than others (like poverty, the nature of the disease, and side-effects).
1,2 Also, psychosocial factors like beliefs about medication, self-efficacy, and social support can be promising intervention targets. These are mostly modifiable (in contrast to factors like poverty or side-effects), and according to reviews of cross-sectional studies, they appear to be associated with non-adherence in various somatic, chronic conditions. [6] [7] [8] [9] [10] [11] [12] [13] Beliefs about medication were the most powerful predictors of adherence (among demographic and medical factors) in one cross-sectional study, 9 while another cross-sectional study identified low-self-efficacy as a significant predictor of non-adherence across different countries, for example. 11 However, there is no insight into psychosocial factors predicting non-adherence in longitudinal studies with a longer follow-up period ($3 months). Such knowledge would be helpful in designing effective adherence interventions in clinical practice. This is the first review which aims to systematically synthesize evidence of longitudinal associations between psychosocial predictors and CPMM non-adherence across adult patients living in Western countries. Since non-adherence literature is scattered across diseases, 14 we combined studies from various somatic, chronic conditions to increase the robustness of our findings.
Methods
PRISMA-guidelines were followed in performing this systematic review. 15 The steps taken regarding data searches, study selection, data extraction, study quality assessment, data synthesis, and data analyses are elaborated below.
Data sources and searches
In March 2011, according to a pre-defined search strategy, four electronic databases (PUBMED, EMBASE, CINAHL, and PsychINFO) were searched for studies up to February 2011. With this search, a first set of studies was included, the reference lists of these studies were hand searched to find additional studies. The studies were also entered into the ISI Web of Knowledge citation index (August 2011). The resulting list of studies, citing one of the initial included studies in our review, was also searched.
The search strategy (see Supplementary Materials) contains key words on medication adherence, chronic, somatic diseases, adults, longitudinal designs, and Western countries. Countries in Africa, Latin-America, SouthAmerica, Asia (excluding Indonesia and Japan), and Turkey were considered as non-Western according to Statistics Netherlands. 16 Non-Western countries were excluded because underlying mechanisms of medication non-adherence could differ from those in Western countries due to socio-economic and cultural differences. 17 In this review, we focused on two of the three components of adherence (ie, on initiation and implementation adherence, thus the extent to which a patient's actual medication dosing regimen corresponds with the prescribed dosing regimen from initiation to last dose). We did not include discontinuation of medication. 1 As using CPMM terms in the search strategy was unfeasible, we used the corresponding diseases for which the CPMMs were prescribed as search terms instead. The disease terms were selected as follows: 1. Chronic preventive maintenance medications were defined. CPMMs were regarded as drugs that 1) are intended to be used chronically to prevent the occurrence or worsening of a disease or its complications; and 2) may have an immediate effect, but must also have a long-term effect (.3 months).
From the full November 2010 Anatomical Therapeutic
Chemical Classification System (ATC) 
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Study selection
Studies were selected based on the criteria in Table 1 . Studies exclusively recruiting subpopulations in special conditions (like prisoners, pregnant women) were excluded. Their results only pertain to a specific group of patients, therefore, including them might have introduced bias into this systematic review.
Two reviewers (BvdB and HZ) independently assessed studies for eligibility in two phases: 1) screening based on title and abstract; and 2) screening based on full text. Disagreements between BvdB and HZ were resolved by discussion; a third reviewer (CvdE) made decisions in case disagreements could not be resolved. Studies in Spanish or Portuguese were judged by LvdA. During the study selection process, three authors were contacted about statistics, outcome measure, or study design to determine eligibility for this review. [20] [21] [22] Data extraction and quality assessment For data extraction, a literature-based, standard form was developed. 23, 24 Information regarding study setting, design, descriptive statistics, measures, and analysis were extracted by HZ; BvdB arbitrarily selected 15% of the included studies to check appropriateness of all extracted data of these studies, and also checked all doubts indicated on the form by HZ.
If multiple adherence measures were presented in one study (eg, about dosing, timing, or taking medication) 25 , we only extracted data about taking medication. Two authors were contacted during the extraction process to check the duration of a follow-up period of $3 months 26 or to explain ambiguities. 19 We adapted the framework developed by Hayden et al 27 to judge methodologic study quality. Our framework contained 23 items divided into six bias domains: study participation, study attrition, prognostic, outcome and confounding measurement, and analyses. Each item was scored as 'yes' (no unacceptable amount of bias introduced), 'partly' (/unsure), and 'no' (unacceptable amount of bias introduced). For every bias domain, a transparent method was used to reach overall judgment about the presence or absence of bias (see Table S1 ). Studies with $four domains judged as 'yes' were considered high-quality studies; studies with ,four domains were considered low-quality studies.
Using three randomly selected studies not included in the review, the framework was piloted by BvdB and HZ, who also performed the actual quality assessment. Disagreements were resolved by discussion and, when necessary, a third reviewer (CvdE) made final decisions. On the domain level, a weighted extent of agreement between BvdB and HZ (quadratic weighting scheme) was calculated due to the ordinal nature of the scores.
28,29

Data synthesis and analysis
Because over 70 non-identical psychosocial predictors (nonidentical by name and/or measurement instrument) were studied in this review, and because of the variety of instruments used to measure non-adherence, a qualitative instead ‡ with straightforward, we mean that participants were directly asked to indicate how many medication doses they missed. For example: "How many pills did you take this week?"; § follow-up period = number of months between baseline (unless indicated otherwise) and last adherence measurement; || this column shows the number of psychosocial predictors measured in the concerning study, and the assigned psychosocial category. Details about the single predictors are presented in Table S2 . A = Beliefs and cognitions about I) medication and treatment; II) illness; III) self-efficacy and locus of control. B = coping styles i) task oriented, ii) emotion oriented. C = Social influences and social support I) regarding medical caregiver; II) regarding friends and family; III) in general. D = personality traits. e = psychological well-being: i) mood state; ii) perceived stress/stressors; ¶ no = no significant association between psychosocial category and medication adherence/nonadherence within study when P#0.05; Yes = significant association when P#0.05; U: univariate; M: multivariate; **to determine methodological quality, six bias domains per study were judged. Here, the total amount of bias free domains is reported (for further details, see 
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Psychosocial predictors of medication non-adherence: review of a quantitative analysis was considered to be appropriate. 30 Therefore, the results regarding associations between psychosocial predictors and medication non-adherence were qualitatively synthesized in four steps.
In step 1, psychosocial categories were formulated. Initially, all psychosocial elements as mentioned in general health behavior models and theories 31, 32 were listed (HZ). Subsequently, based on consensus, the elements were clustered by HZ and three psychologists (SvD, JV, and LK) resulting in the categories of Figure 1 .
Next, the psychosocial predictors within the studies of the review were assigned to one of the categories in Figure 1 (HZ and the psychologists). In this way, the considerable number of single, non-identical predictors was dealt with.
In step 2, for each psychosocial predictor within a category and within a study, the presence of a significant univariate and multivariate association with medication non-adherence was determined (see Table S2 ). Statistical significance was set at P,0.05.
In step 3, results within studies were synthesized per psychosocial category. When $75% of variables within a single psychosocial category were significantly and consistently (ie, same predictors in same direction) associated with non-adherence, a 'yes' was assigned (ie, association present). When $75% of variables were significantly, but inconsistently, associated (eg, four of five predictors in category about depressive symptoms, of which two are positively related to non-adherence and two are negatively related), the term 'conflicting' was assigned. When ,75% of variables were significantly and consistently associated, a 'no' was assigned. Multivariate results were preferably used to synthesize results in this step. When multivariate results were not reported, univariate results were used.
In the fourth and final step, a best evidence synthesis (BES) per psychosocial category between studies was performed to summarize evidence of longitudinal associations between the predictors in the psychosocial 
Measures and results
Adherence
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Zwikker et al categories and medication non-adherence. We defined four levels of evidence as used in previous reviews of longitudinal studies: 60 -62 1. Strong evidence: consistent findings ($75% of studies within psychosocial category report same conclusion about association; ie, 'yes, present' or 'no, not present') in at least two high-quality studies. 2. Moderate evidence: consistent findings in one highquality study AND at least two low-quality studies. 3. Limited evidence: findings in one high-quality study OR consistent findings in at least two low-quality studies. 4. Conflicting evidence: inconsistent findings in at least two studies irrespective of study quality (ie, ,75% of studies report same conclusion about association).
Note that this level of evidence was checked first before assigning strong, moderate or limited evidence level to a category. The level of evidence was undeterminable when #one study of low quality was available for a psychosocial category.
Sensitivity analyses were performed to examine the robustness of findings, regarding the cut-off point for methodological quality, diseases, adherence measurement, and statistical analyses (ie, focusing on univariate analyses only). Also, an additional analysis on single predictors was carried out, since associations between single predictors like 'avoidance coping' and non-adherence could be overshadowed by combining them into a single category with generally non-significant psychosocial predictors, such as hopelessness and confusion. Three steps were taken: 1) all significant predictors (P#0.05) were listed; 2) each of these predictors was grouped with identically named, significant and non-significant predictors; and 3) when at least two studies were available for those predictors, the BES rules were applied.
Results
Study inclusion
Of 4,732 non-duplicate references, 30 met our inclusion criteria ( Figure 2) . 19, 25, 26, In all, 1,255 records were identified by screening the reference lists and the ISI Web of Knowledge citation index of the initial included studies.
Initially, the percentage of agreement regarding the eligibility of studies was 86% (of the 272 studies selected on title and abstract, agreement was obtained in about 235 studies after reading the full-text). Disagreements were mainly due to misconceptions about psychosocial predictors (eg, clinically diagnosed depression versus symptoms of depression), study design, and adherence measure (ie, discontinuation or execution adherence). For one study, 52 disagreement could not be resolved by discussion and thus a final decision was made by CvdE. Table S2 .
Study characteristics and quality assessment
The included studies (all based on different data sets) covered CPMMs for asthma, diabetes, heart diseases/hypertension, human immunodeficiency virus (HIV), and organ transplants. Medication type was not explicitly mentioned in four studies, 37, 38, 45 ,59 but we assumed CPMM was used since CPMM is the standard medical treatment for the 20 selected diseases in this review. In most studies, patients were recruited from medical clinics or hospitals and the sample size ranged from 50-1,911. Attrition rates varied from 0%-71%. Participants were predominantly men and often $37 years of age and a disease duration of .2 years. The observation period between baseline and last adherence measurement was $3 and ,12 months in ten studies and $12 months in 20 studies, with a maximum of 60 months. Medication adherence was mostly measured by self-report (18 studies, predominantly questionnaires); seven studies used a validated adherence questionnaire. 33, 36, 43, 46, [49] [50] [51] Other adherence measurements were carried out by reviewing medical records or the medication event monitoring system (MEMS). In 15 studies, both univariate and multivariate analyses were reported.
All 30 included studies were judged to be 'low-quality' (Table S3) . This was mainly due to poor descriptions and/ or bias regarding the study sample, the use of non-validated questionnaires, the lack of accounting for confounding variables, and a poor description of the data analyses. Most studies, moreover, did not appropriately describe actions taken in case of missing data.
A total of 180 bias domains were judged (30 studies by six domains). Initially, BvdB and HZ fully agreed on 78 domains, partially agreed (ie, 'partly' versus 'no' or 'partly' versus 'yes') on 79 domains and fully disagreed (eg, 'yes' versus 'no') on 23 domains, resulting in a weighted agreement of 76%. Disagreements were caused by poor description of methods, different interpretations of missing data, differences in calculating study attrition rates, and different interpretations regarding the appropriateness of study sample descriptions. On this latter point, disagreements about three studies 35 No CPMM: n=6
Living in non-Western country: n=4
No somatic, chronic disease as specified in search strategy: n=2
Other (eg, thesis): n=5
Full-text articles meeting selection criteria / included n=30
Figure 2
Flowchart of study inclusion process. Abbreviation: CPMM, chronic preventive maintenance medication.
Best evidence synthesis Table 3 shows there is limited evidence for the absence of a longitudinal association with medication non-adherence in all of the eleven psychosocial subcategories.
Beliefs and cognitions
Regarding category AI (beliefs and cognitions about medication and treatment), two of nine studies found a longitudinal, multivariate association between having a positive attitude towards taking medication and adherence (odds ratio [OR] =1.56, 95% confidence interval [CI] 1.18, 2.06), 43 and between necessity beliefs and concern beliefs about medication and adherence (OR =2.19, 95% CI 1.02, 4.71 and OR =0.45, 95% CI 0.22, 0.96, respectively). 49 One other study 33 found univariate associations between necessity and concern beliefs about medication and adherence, but these associations did not hold in the multivariate analysis.
One study demonstrated a longitudinal, multivariate association between low self-efficacy and medication non-adherence; 53 however, the effect size was small. Univariate, but not multivariate associations between self-efficacy and adherence were demonstrated in two studies.
55,57
Coping styles
No univariate and multivariate associations were found between the task-oriented coping style category and medication adherence.
Regarding emotion-oriented coping styles, one of six studies revealed a multivariate association with non-adherence (eg, OR of 9.71 for avoidance coping). 56 Furthermore, avoidance coping as a single predictor was associated with non-adherence in three of four studies measuring this construct.
25,40,56
Social influences and social support
Two of the 25 studies demonstrated significant associations between predictors within the category social influences and social support and (non-)adherence, but only one of these studies reported on a multivariate association between having support from a partner and non-adherence (regression coefficient =−0.15, 95% CI −0.25, −0.05).
51 Receiving practical social support was associated with better adherence as a single predictor.
38,41
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Personality traits
One of eight studies showed a multivariate, longitudinal association between the category of personality traits and medication non-adherence: 26 a lower sense of coherence (a global life orientation in which life is perceived as comprehensible, manageable and meaningful) 63 was associated with greater non-adherence (OR=0.55, CI 0.31-0.96). Associations between other predictors within the personality traits category and non-adherence were lacking.
Psychological well-being
Regarding categories EI (mood state) and EII (perceived stress/stressors), no associations between predictors in those categories and medication non-adherence could be established for the vast majority of studies (24 out of 29). Two of the five studies which did show significant associations reported on multivariate analyses: the regression coefficient for depressive symptoms was 0.18 (95% CI 0.07, 0.29) in predicting non-adherence; 51 the standardized beta for health distress was −0.22 (CI not reported) for predicting adherence.
59 Table S2 can be consulted for detailed information about associations between single psychosocial predictors and medication adherence/non-adherence.
Sensitivity analyses
The sensitivity analyses confirmed that, generally, no association was found between the psychosocial categories and medication non-adherence (Table S4) .
The additional analysis on single predictors showed no association between most single, psychosocial predictors and medication non-adherence. However, conflicting evidence was found for having a positive attitude towards taking medication, 37 ,43 necessity beliefs and concern beliefs about medication, 33, 49 self-efficacy in medication-taking, 25, 33, 43, 47, 53, 54 the coping style "planful problem solving", 25, 41 and (the number of) stressful (life) events. 38, 42, 46 Limited evidence was found for an association between escape-avoidance coping and medication non-adherence, 25, 41, 56, 59 and for an association between receiving practical, social support and medication adherence.
38,41
Discussion
To the best of our knowledge, this is the first systematic review summarizing evidence of longitudinal associations between psychosocial factors and non-adherence to CPMM, irrespective of somatic disease. Due to the low quality of the included studies, limited evidence was found for absence of longitudinal associations between categories of psychoso- 
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Psychosocial predictors of medication non-adherence: review cial predictors and medication non-adherence. In general, findings were robust according to sensitivity analyses. Our findings of longitudinal associations between psychosocial factors and medication non-adherence are in line with the few conducted cross-sectional studies about associations between medication adherence, coping styles, personality traits, and psychosocial well-being (except depressive symptoms) in somatic conditions. The findings in these cross-sectional studies are ambiguous at best. 8, [64] [65] [66] [67] [68] For example, an active coping style was associated with medication adherence in some studies 8, 68 but not in others, 64, 66 and stress was associated with lesser adherence in a study of Holt et al, 67 but was unrelated to non-adherence in a study of Ediger et al. 65 In contrast to coping styles and personality traits, depression is often studied as possible predictor of medication non-adherence. Here, our results are not in line with results from other reviews, reporting depression to be a predictor of medication non-adherence. 6, [69] [70] [71] [72] [73] [74] Initially, this discrepancy might be explained by the fact that clinical depression is within the scope of most other studies, but beyond the scope of our systematic review since we did not study morbidity as a predictor of non-adherence; instead, we studied depressive symptoms. Second, an explanation might be that those other reviews included studies with mainly cross-sectional designs. Feelings of depression might increase and decrease over the course of a disease. A high degree of depressive feelings might correlate well with non-adherent behavior at that same time, but just might not be predictive of non-adherent behavior in the future due to this changeability. Thus, longitudinal associations between depressive feelings and non-adherence might not be applicable.
This thought might also apply to discrepancies in findings between our review and other reviews on associations between beliefs about medication/treatment, poor social support, and non-adherence. These other reviews underline the importance of beliefs about medication/treatment and poor social support in predicting medication non-adherence 6, 10, [69] [70] [71] [72] [73] [74] [75] [76] in contrast to our review findings, but again, those other reviews are mainly based on studies with cross-sectional designs.
In terms of internal validity, a strength of this review is that we, in contrast to others, systematically defined and categorized psychosocial factors. By doing so, we were able to 1) draw a concise number of conclusions about associations between psychosocial predictors and medication non-adherence in a reproducible manner; 2) address the heterogeneity between single, psychosocial predictors; and 3) address an important goal of a systematic review: converging information. The pitfall of categorization (eg, the possibility of overlooking significant associations between certain, single predictors and non-adherence, by pooling them with other types of [non-significant] predictors), was avoided by performing an extended sensitivity analysis on single predictors. This analysis revealed our conclusions to be robust for almost all single, psychosocial predictors included in this review.
Another strength of this review is that we systematically synthesized results using a best evidence synthesis in contrast to most other reviews, which tend to be characterized by narrative designs. 6, 10, 69, 70, 73, 74, 76 Narrative designs often do not rely on systematic methods to assign weight of evidence; eg, by incorporating methodological quality of included studies. 77 Although no review procedure eliminates the chance that reviewers' biases will affect the conclusions drawn, 77 the application of a best evidence synthesis makes a review procedure transparent and reproducible.
A limitation of this systematic review is that we used chronic disease terms instead of medication terms in the search strategy and, consequently, we may have missed relevant studies about chronic preventive maintenance medication. However, we assume that the number of missed studies is minimal, since diseases are usually mentioned in medication adherence studies.
Another limitation could be the use of results of univariate analyses to draw conclusions about associations in the absence of multivariate analysis data, as univariate analyses could lead to an overestimating of the strength of associations. However, our sensitivity analyses on data from univariate analyses confirmed the robustness of our findings.
Concerning external validity, a strong feature of this review is that it focused exclusively on longitudinal associations between psychosocial predictors and medication non-adherence, thereby providing insight into the temporality and robustness of associations. However, only 5 of the 30 studies included in our review corrected for baseline non-adherence. 34, 50, 53, 58, 59 Failure to account for baseline non-adherence when suggesting predictive longitudinal associations is considered a liberal approach, 78 since baseline non-adherence is likely to explain a substantial part of the variance in non-adherence over time. Because we did not find any associations using a liberal approach, however, we believe it is unlikely that handling a strict longitudinal approach in this review would have altered our findings.
Another limitation concerning external validity is that the poor quality of the included studies prevented us from drawing firm conclusions about the lack of associations between psychosocial predictors and medication adherence 
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The lack of a gold standard for adherence measurement 73 also restricts the validity of our findings. The adherence measures used in the included studies of this review (self-report, refill data, and electronic monitoring) do not measure actual ingestion, and the use of self-report and electronic monitoring might have introduced response bias because of participants' awareness of the measurements. However, all medication adherence related research has to deal with the limitations of adherence measurements. For now, our review provides the best evidence currently available, and clearly demonstrates the need for more high-quality, longitudinal research into associations between psychosocial predictors and medication non-adherence.
Two recommendations for future research can be made. First, future longitudinal research into psychosocial predictors of medication non-adherence should be of high quality. Researchers should, for example, use valid measures of psychosocial predictors and medication non-adherence and should thoroughly describe which steps were performed in the study, especially those relating to handling missing data and avoiding bias.
Second, the research gap in longitudinal studies into associations between psychosocial predictors and medication non-adherence in patients with conditions such as rheumatic diseases, migraine disorders, gout, glaucoma, and stomach ulcers (see Supplementary Materials) should be complemented. Although we assume that review findings will also apply to these diseases, this assumption needs to be confirmed.
The conclusion of this systematic review is that there is limited evidence for absence of longitudinal associations between psychosocial predictors and medication nonadherence. Consequently, our results do not provide psychosocial targets for the development of new interventions in clinical practice. However, the usefulness of psychosocial predictors in improving medication adherence should not be ruled out, as more high-quality research is needed to confirm or refute the conclusion of this review. Such future research could also further explore the associations found in this review between escape-avoidance coping and medication non-adherence, and between receiving practical, social support and medication adherence.
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Psychosocial predictors of medication non-adherence: review 20. Kuo YF, Raji MA, Markides KS, Ray LA, Espino DV, Goodwin JS. 1.2. The (baseline) study sample is adequately described by key characteristics (descriptive data about age, sex, diagnosis, disease duration and medication type/group), and no unacceptable level of bias is present 1.3. The method of recruitment or sampling is adequately described. if method of recruitment is not 'consecutive', then, for example, descriptions are given about the sampling frame, numbers, methods to identify the sample (such as a description of referral patterns in health care) and period of recruitment, and no unacceptable level of bias is present 1.4. inclusion and exclusion criteria are adequately described, and no unacceptable level of bias is present 1.5. There is adequate participation in the study by eligible individuals (power analysis is described or the sample size (n) is adequate in relation to the number of prognostic variables (K) in the statistical analyses (ratio n:K exceeds 10:1) 2. Study attrition 2.1. Response rate (ie, proportion of study sample completing the study and providing outcome data) is adequate if study sample size #50 participants: 'yes' when total number of participants lost to follow-up was ,10% at followup $three months. 
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Zwikker et al Table S1 (Continued)
Bias domain Criterion
5.2.
A clear description of the most important confounders measured is provided AND/OR measures/ methods of the most important confounders (at baseline) are adequately described to allow assessment of their validity and reliability. No unacceptable level of bias is present ○ Objective measures (such as age, sex) and clear description = 'yes'. Poor/no description is 'partly' ○ validated, subjective measures (eg, opinions) and clear description = 'yes'. Poor/no description = 'partly' ○ Non-validated, subjective measures and clear description = 'partly'. Poor/no description = 'no' 5.3. The method and setting of confounding measurement are the same for all study participants at baseline 5.4. important potential confounders are accounted for in the study design (eg, matching for key variables/ restriction) OR in analysis (stratification/multivariate techniques) 5.5. Authors appropriately described and dealt with missing confounding data 6. Analysis 6.1. There is sufficient presentation of data to assess the adequacy of the analysis 'Yes', if main findings of the study and statistical methods used are clearly described: simple outcome data, crude data and estimates of random variability should be reported, so that the reader can check the major analyses and conclusions 6.2. The statistical tests used to assess the main outcome are appropriate For example, non-parametric methods should be used for small sample sizes 6.3. The strategy for model building (ie, inclusion of variables) is appropriate, and is based on conceptual thoughts, a framework or a model For example: variables that do not correlate with the main outcome of interest are not used in multivariate analysis. Proper variables are entered in logical steps into the multivariate model 6.4. The selected model is adequate for the design of the study For example: in repeated measures, a repeated-measure model should be used. if outcome is binominal, logistic regression should be used, etcetera. if delta outcome is being investigated, models should to be adjusted for baseline outcome values 
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Zwikker et al Table S2 explanation of measures and results* 39 Tendency to use avoidance coping (instrument NR) Notes: *NS (non significant): as reported in the concerning study. UD (undetermined): because of inadequate description in the concerning study. † Binary outcome measure, unless indicated otherwise. with a straightforward question, we mean that participants were directly asked to indicate how many medication doses they missed. For example: "How many pills did you take this week?"; ‡ followup period = number of months between baseline (unless indicated otherwise) and last adherence measurement; § if no instrument is mentioned for predictor, then previous mentioned instrument is applicable; || psychosocial category, to which a predictor was assigned. A = Beliefs and cognitions about: I) medication and treatment; II) illness; III) self-efficacy and locus of control. B = coping styles: i) task oriented, ii) emotion oriented. C = Social influences and social support: I) regarding medical caregiver; II) regarding friends and family; III) in general. D = personality traits. e = psychological wellbeing: i) mood state; ii) perceived stress/stressors; ¶ OR: Odds Ratio (95% confidence interval). OR ,1 = lower chance of being adherent or non-adherent (for direction in relevant study, see column "Adherence, follow-up period") when predictor increases or when predictor ≠ reference category. OR .1 = greater change of being adherent or non-adherent when predictor increases (or when predictor ≠ reference category). Scores other than OR are the mean predictor scores with standard deviation, unless indicated otherwise; **+ = higher level of predictor implies higher adherence at level P#0.05; − = higher level of predictor implies less adherence at P#0.05; 0 = no significant association between predictor and adherence at P#0.05; ? = association present, but direction unclear; † † to determine methodological quality, six bias domains per study were judged. Here, the total amount of bias free domains is reported (for further details, see table S3); ‡ ‡ assumed that all variables, tested by univariate analysis, were also tested by multivariate analysis; § § retrospective design; || || Diagnosis for coronary heart disease, hypertension, diabetes mellitus and/or hyperlipidaemia; ¶ ¶ not reported in study is interpreted by HZ/BvdB as not significant; ***significance of P#0.05 assumed by HZ/BvdB; † † † negative association assumed; ‡ ‡ ‡ type of medication is immunosuppressants, antihypertensives, and/ or antivirals; § § § use of chronic preventive medication assumed; || || || unexpected direction. Abbreviations: AACTG, adult AIDS clinical trials group; ALTMBSES, adapted long term medication behavior self efficacy scale; AGSRP, adapted gay service research project; AIDS, acquired immunodeficiency syndrome; AMHI, adapted mental health inventory; APIAQ, adapted protease inhibitor attitude questionnaire; ART, antiretroviral therapy; ASBSI, anxiety subscale of brief symptom inventory; ATS, anxiety trait scale; ATSFDS, adapted version of transplant symptom frequency and distress scale; AwC, adapted ways of coping; BDi, beck depression inventory; BHLeS, buffalo Hiv life events survey; BHS, beck hopelessness scale; BMiCiS, Billings and Moos inventory of coping with illness styles; BMQ, beliefs about medication questionnaire; BST, Burnam interviewer-administered 8-item screening tool; CeS-D, center for epidemiologic studies depression scale; CMHS, Cook-Medley hostility scale; DAS, dyadic adjustment scale; Di, dysregulation inventory; DOS, dispositional optimism scale; DSBSi, depression subscale of brief symptom inventory; DSPeRi, demoralization scale of psychiatric epidemiology research interview; FRi, family relations index (from family environment scale); FTSSH, Finnish twin study scale of hostility; GHQ, general health questionnaire; HAART, highly active antiretroviral therapy; HADS, hospital anxiety and depression scale; HAT-QOL, Hiv/AiDS-targeted quality of life instrument; HBS, health behaviour scale; HCSUS, HIV cost and services utilization study; HIE, Horowitz impact of events scale; HIS, health intention scale; HIV, human immunodeficiency virus; HMO, health maintenance organization; iCS, inhaled corticosteroids; iDD, inventory to diagnose depression; iQR, interquartile range; iSeL, interpersonal support evaluation list; LeS, life experience survey; LOT-R, life orientation test; LSS, life stressors scale; LTMSES, long term medication self-efficacy scale; MAH, mental adjustment to HIV; MARS, medication adherence report scale; MAS, Miller attitude scale; MASRi, medication adherence self-report inventory; MeMS, medication even monitoring system; MHLCS, multidimensional health locus of control scale; MOS, medical outcome study health survey; MS, Memphis survey; NEO-FFI, NEO five factor inventory; NR, not reported; NS, non-significant; NSEPQSS, neuroticism scale of the Eysenck personality questionnaire-revised short scale; NT, not tested; OR, odds ratio; Pat SS, patient satisfaction scale; PEI, psychiatric epidemiology interview; POMS, profiles of mood states; PPCS, perceived parenting competence scale; PRQ, personal resource questionnaire; PSS, perceived stress scale; RSeQR, Rosenberg self-esteem questionnaire; SC, symptom checklist; SCL-90, Symptom Checklist-90-R; SeM, standard error of the mean; SF-36, short form-36 health survey; SMS, sense of mastery scale; SOC, sense of coherence; SPS, social provision scale; SSAi, social support appraisals index; SSAS, social support appraisal scale; SSQ, social support questionnaire; TSQ, transplant stress questionnaire; vAS, visual analog scale.
